Showing 463 results
-
Media Release /At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase…
-
Media Release /New post hoc data from the Phase III EXPAND trial showed combined high levels of plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) were consistently…
-
Media Release /Primary analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate with one-time Kymriah infusion(1) Robust response observed in heavily pretreated patients in…
-
Media Release /Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple…
-
Media Release /- Nearly 70% of patients maintained platelet counts of ≥30×10[9]/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding- More than one-third of patients permanently…
-
Media Release /Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients…
-
Media Release /- Promacta (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic…
-
Media Release /- Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate…
-
Media Release /Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC)…
-
Media Release /- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients…
